311 related articles for article (PubMed ID: 31796212)
41. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
[TBL] [Abstract][Full Text] [Related]
42. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Arthritis Res Ther; 2022 Apr; 24(1):88. PubMed ID: 35443675
[TBL] [Abstract][Full Text] [Related]
43. Pegloticase for chronic gout.
Anderson A; Singh JA
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366
[TBL] [Abstract][Full Text] [Related]
44. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
Morillon MB; Nørup A; Singh JA; Dalbeth N; Taylor WJ; Kennedy MA; Pedersen BM; Grainger R; Tugwell P; Perez-Ruiz F; Diaz-Torne C; Edwards NL; Shea B; Ellingsen TJ; Christensen R; Stamp LK;
Semin Arthritis Rheum; 2023 Jun; 60():152191. PubMed ID: 36963128
[TBL] [Abstract][Full Text] [Related]
45. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
46. What Is the Evidence for Treat-to-Target Serum Urate in Gout?
Bursill D; Dalbeth N
Curr Rheumatol Rep; 2018 Mar; 20(3):11. PubMed ID: 29516287
[TBL] [Abstract][Full Text] [Related]
47. Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.
Fautrel B; Belhassen M; Hudry C; Woronoff-Lemsi MC; Levy-Bachelot L; Van Ganse E; Tubach F
Joint Bone Spine; 2020 Mar; 87(2):137-139. PubMed ID: 31669808
[TBL] [Abstract][Full Text] [Related]
48. Management of Gout in a Hospital Setting: A Lost Opportunity.
Wright S; Chapman PT; Frampton C; O'Donnell JL; Raja R; Stamp LK
J Rheumatol; 2017 Oct; 44(10):1493-1498. PubMed ID: 28765252
[TBL] [Abstract][Full Text] [Related]
49. What do I need to know about gout?
Becker MA; Ruoff GE
J Fam Pract; 2010 Jun; 59(6 Suppl):S1-8. PubMed ID: 20544070
[TBL] [Abstract][Full Text] [Related]
50. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Schumacher HR; Becker MA; Lloyd E; MacDonald PA; Lademacher C
Rheumatology (Oxford); 2009 Feb; 48(2):188-94. PubMed ID: 19141576
[TBL] [Abstract][Full Text] [Related]
51. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
52. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
Topless R; Noorbaloochi S; Merriman TR; Singh JA
Semin Arthritis Rheum; 2022 Oct; 56():152057. PubMed ID: 35835008
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial.
Sun R; Lu J; Li H; Cheng X; Xin Y; Li C
Joint Bone Spine; 2020 Oct; 87(5):461-466. PubMed ID: 32302693
[TBL] [Abstract][Full Text] [Related]
54. Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial.
Satpanich P; Pongsittisak W; Manavathongchai S
Clin Rheumatol; 2022 Jan; 41(1):213-221. PubMed ID: 34406530
[TBL] [Abstract][Full Text] [Related]
55. Gout.
Dalbeth N; Gosling AL; Gaffo A; Abhishek A
Lancet; 2021 May; 397(10287):1843-1855. PubMed ID: 33798500
[TBL] [Abstract][Full Text] [Related]
56. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
Soskind R; Abazia DT; Bridgeman MB
Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
[TBL] [Abstract][Full Text] [Related]
57. Patient factors and health outcomes associated with illness perceptions in people with gout.
Selvadurai D; Coleshill MJ; Day RO; Briggs NE; Schulz M; Reath J; Aung E
Rheumatology (Oxford); 2024 Jul; 63(7):1927-1937. PubMed ID: 37769230
[TBL] [Abstract][Full Text] [Related]
58. Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey.
Singh JA; Edwards NL
J Clin Rheumatol; 2020 Jun; 26(4):129-133. PubMed ID: 32453285
[TBL] [Abstract][Full Text] [Related]
59. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
Keenan RT
Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Nov; 82(9):763-769. PubMed ID: 37233824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
